0000874015-24-000106.txt : 20240202
0000874015-24-000106.hdr.sgml : 20240202
20240202195515
ACCESSION NUMBER: 0000874015-24-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOUGEN ELIZABETH L
CENTRAL INDEX KEY: 0001074773
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 24593546
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
STREET 2: C/O IONIS PHARMACEUTICALS, INC.
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330336973
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-02-01
0
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001074773
HOUGEN ELIZABETH L
2855 GAZELLE COURT
CARLSBAD
CA
92010
0
1
0
0
EVP, Finance & CFO
0
Common Stock
2024-02-01
4
A
0
4140
0.0
A
95030
D
Common Stock
2024-02-02
4
S
0
2125
49.5399
D
92905
D
Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Performance restricted Stock Unit Agreement and Grant Notice.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.53 to $49.55 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
By: Patrick R. O'Neil, attorney-in-fact For: Elizabeth L. Hougen
2024-02-02